117 related articles for article (PubMed ID: 33999509)
41. Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G.
Rose KM; Marin M; Kozak SL; Kabat D
AIDS Res Hum Retroviruses; 2005 Jul; 21(7):611-9. PubMed ID: 16060832
[TBL] [Abstract][Full Text] [Related]
42. Multifaceted counter-APOBEC3G mechanisms employed by HIV-1 Vif.
Britan-Rosich E; Nowarski R; Kotler M
J Mol Biol; 2011 Jul; 410(5):1065-76. PubMed ID: 21763507
[TBL] [Abstract][Full Text] [Related]
43. Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure.
Kim EY; Bhattacharya T; Kunstman K; Swantek P; Koning FA; Malim MH; Wolinsky SM
J Virol; 2010 Oct; 84(19):10402-5. PubMed ID: 20660203
[TBL] [Abstract][Full Text] [Related]
44. Replication protein A (RPA) hampers the processive action of APOBEC3G cytosine deaminase on single-stranded DNA.
Lada AG; Waisertreiger IS; Grabow CE; Prakash A; Borgstahl GE; Rogozin IB; Pavlov YI
PLoS One; 2011; 6(9):e24848. PubMed ID: 21935481
[TBL] [Abstract][Full Text] [Related]
45. An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.
Bennett RP; Stewart RA; Hogan PA; Ptak RG; Mankowski MK; Hartman TL; Buckheit RW; Snyder BA; Salter JD; Morales GA; Smith HC
Antiviral Res; 2016 Dec; 136():51-59. PubMed ID: 27825797
[TBL] [Abstract][Full Text] [Related]
46. APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription.
Li XY; Guo F; Zhang L; Kleiman L; Cen S
J Biol Chem; 2007 Nov; 282(44):32065-74. PubMed ID: 17855362
[TBL] [Abstract][Full Text] [Related]
47. HIV-1 Vif inhibits G to A hypermutations catalyzed by virus-encapsidated APOBEC3G to maintain HIV-1 infectivity.
Wang Y; Kinlock BL; Shao Q; Turner TM; Liu B
Retrovirology; 2014 Oct; 11():89. PubMed ID: 25304135
[TBL] [Abstract][Full Text] [Related]
48. Phosphorylation of APOBEC3G by protein kinase A regulates its interaction with HIV-1 Vif.
Shirakawa K; Takaori-Kondo A; Yokoyama M; Izumi T; Matsui M; Io K; Sato T; Sato H; Uchiyama T
Nat Struct Mol Biol; 2008 Nov; 15(11):1184-91. PubMed ID: 18836454
[TBL] [Abstract][Full Text] [Related]
49. Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G.
Nguyen DH; Gummuluru S; Hu J
J Virol; 2007 May; 81(9):4465-72. PubMed ID: 17314171
[TBL] [Abstract][Full Text] [Related]
50. Hepatitis B virus X protein is capable of down-regulating protein level of host antiviral protein APOBEC3G.
Chen R; Zhao X; Wang Y; Xie Y; Liu J
Sci Rep; 2017 Jan; 7():40783. PubMed ID: 28098260
[TBL] [Abstract][Full Text] [Related]
51. Structural Determinants of the APOBEC3G N-Terminal Domain for HIV-1 RNA Association.
Fukuda H; Li S; Sardo L; Smith JL; Yamashita K; Sarca AD; Shirakawa K; Standley DM; Takaori-Kondo A; Izumi T
Front Cell Infect Microbiol; 2019; 9():129. PubMed ID: 31165049
[TBL] [Abstract][Full Text] [Related]
52. The HDAC6/APOBEC3G complex regulates HIV-1 infectiveness by inducing Vif autophagic degradation.
Valera MS; de Armas-Rillo L; Barroso-González J; Ziglio S; Batisse J; Dubois N; Marrero-Hernández S; Borel S; García-Expósito L; Biard-Piechaczyk M; Paillart JC; Valenzuela-Fernández A
Retrovirology; 2015 Jun; 12():53. PubMed ID: 26105074
[TBL] [Abstract][Full Text] [Related]
53. Atomic force microscopy studies of APOBEC3G oligomerization and dynamics.
Shlyakhtenko LS; Lushnikov AY; Miyagi A; Li M; Harris RS; Lyubchenko YL
J Struct Biol; 2013 Nov; 184(2):217-25. PubMed ID: 24055458
[TBL] [Abstract][Full Text] [Related]
54. APOBEC3G/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc or Efavirenz.
Covino DA; Purificato C; Catapano L; Galluzzo CM; Gauzzi MC; Vella S; Lefebvre E; Seyedkazemi S; Andreotti M; Fantuzzi L
Front Immunol; 2018; 9():1839. PubMed ID: 30135687
[TBL] [Abstract][Full Text] [Related]
55. Nanoscale Characterization of Interaction of APOBEC3G with RNA.
Pan Y; Sun Z; Maiti A; Kanai T; Matsuo H; Li M; Harris RS; Shlyakhtenko LS; Lyubchenko YL
Biochemistry; 2017 Mar; 56(10):1473-1481. PubMed ID: 28029777
[TBL] [Abstract][Full Text] [Related]
56. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation.
Santa-Marta M; da Silva FA; Fonseca AM; Goncalves J
J Biol Chem; 2005 Mar; 280(10):8765-75. PubMed ID: 15611076
[TBL] [Abstract][Full Text] [Related]
57. Protective role of histone deacetylase 4 from ultraviolet radiation-induced DNA lesions.
Li S; Zhou M; Ze K; Sun X; Zhao C; Li Z; Lu H; Jiao Y; Wang T; Li S; Hua L; Cai H; Li X
Mol Carcinog; 2020 Nov; 59(11):1292-1301. PubMed ID: 32924161
[TBL] [Abstract][Full Text] [Related]
58. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
Luo K; Wang T; Liu B; Tian C; Xiao Z; Kappes J; Yu XF
J Virol; 2007 Jul; 81(13):7238-48. PubMed ID: 17428847
[TBL] [Abstract][Full Text] [Related]
59. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.
Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X
J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381
[TBL] [Abstract][Full Text] [Related]
60. Uracil DNA glycosylase counteracts APOBEC3G-induced hypermutation of hepatitis B viral genomes: excision repair of covalently closed circular DNA.
Kitamura K; Wang Z; Chowdhury S; Simadu M; Koura M; Muramatsu M
PLoS Pathog; 2013; 9(5):e1003361. PubMed ID: 23696735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
